updated 5/11/2011 8:45:43 AM ET 2011-05-11T12:45:43

BRANFORD, Conn., May 11, 2011 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) today reported financial results for the first quarter of 2011, ending March 31, 2011. Worldwide FORE-SIGHT® Absolute Tissue Oximetry revenues increased to $1.6 million, or 15% over the first quarter of 2010, on the strength of a 58% increase in worldwide FORE-SIGHT disposable sensor sales. 

First Quarter 2011 Highlights:

  • Matthew Herwig hired as Vice President of Global Sales and Marketing in January.
  • Worldwide FORE-SIGHT revenues increase 15% over first quarter 2010.
  • Worldwide FORE-SIGHT disposable sensor revenues increase 58% over first quarter 2010.
  • Domestic FORE-SIGHT disposable sensor revenues increase 48% over first quarter 2010.
  • Domestic field selling force headcount increases by 8 to 34 personnel.

"We are pleased with sales of our FORE-SIGHT Absolute Tissue Oximeter products for the first quarter," said Thomas M. Patton, CASMED's President and CEO, "particularly when compared to very strong international monitor revenues in Q1 of 2010. With the increases we are seeing in both sensor sales and overall revenue, we believe that our efforts to penetrate the tissue oximetry market and increase utilization of our best-in-class FORE-SIGHT technology are beginning to have an impact."

The Company reported total revenues for the first quarter of $5.6 million. Those revenues were in line with the Company's expectations and down $0.5 million from the first quarter of 2010. Absolute Tissue Oximetry revenues were $1.6 million, up 15% over the same period of the prior year, and Traditional Vital Signs Monitoring revenues were $4.0 million, down 11% from prior year.  

Operating expenses increased $0.8 million over the first quarter of 2010 as a result of planned investment increases in Research and Development and in Sales and Marketing, primarily related to the Company's Tissue Oximetry product line. Net losses were $1.2 million, or $(0.09) per basic and diluted share, for the first quarter of 2011, compared to net income of $0.2 million, or $0.02 per basic and diluted share, for the same period of the prior year.

"In the first quarter we made substantial progress in executing our plans to improve our prospects for future growth,"  Mr. Patton continued. "Our R&D programs to revitalize our product lines are on track. Supported by a new Vice President of Global Sales and Marketing hired, we have already begun to strengthen, expand and support our distribution networks. While we are impatient to see overall revenue growth, we are satisfied with the tangible progress made toward our goals to date."

Conference Call Information

CASMED will host a conference call on May 11, 2011 at 10:00 a.m. Eastern Time to discuss first quarter 2011 results. Participants on the call will be Thomas Patton, President and CEO, and Jeffery Baird, CFO.

The live call may be accessed by phone at 877-303-9207 (domestic) or 760-536-5228 (international). If you would like to participate, please call at least ten minutes prior to the start time of 10:00 a.m. Eastern Time.

A live audio webcast of the conference call will also be available on the Company's website located at www.casmed.com. Please allow extra time prior to the call to visit the site and download the streaming media software required to join the webcast. An online archive of the webcast will be available and archived on the website for thirty days.

About CASMED® - Monitoring What's Vital

CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Tissue Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for all patients – adult, pediatric and neonatal – regardless of age or weight. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.

The Company's product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Absolute Tissue Oximeter, and Traditional Vital Signs Monitoring, including bedside patient vital signs monitoring products, proprietary non-invasive blood pressure measurement technology, neonatal intensive care supplies, and service. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.

For further information regarding CAS Medical Systems, Inc., visit the Company's website at www.casmed.com.

The CAS Medical Systems, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4675

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, customer acceptance of the Company's products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders and competitorsand other risks detailed in the Company's Form 10-K for the year ended December 31, 2010 and other subsequent Securities and Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.

  March 31,

Dec 31,

Cash and cash equivalents  $ 2,200,963  $ 4,492,690
Accounts receivable  3,178,525  2,606,616
Income tax receivable  --   13,655
Inventories  4,834,243  4,812,965
Other current assets  344,377  310,187
 Total current assets  10,558,108  12,236,113
Property and equipment  6,992,150  7,053,896
Less accumulated depreciation  (5,143,892)  (5,244,819)
   1,848,258  1,809,077
Intangible and other assets, net  674,616  651,626
 Total assets  $ 13,080,982  $ 14,696,816
Accounts payable  1,518,404  2,283,906
Accrued expenses  1,083,463  909,331
 Total current liabilities  2,601,867  3,193,237
Other liabilities  211,159  211,159
Deferred gain on sale of facilities  865,767  899,426
 Total liabilities  3,678,793  4,303,822
Common stock  54,309  54,302
Additional paid-in capital  10,217,719  10,002,600
Treasury stock  (101,480)  (101,480)
Retained earnings  (768,359)  437,572
Shareholder's equity  9,402,189  10,392,994
Total liabilities & equity  $ 13,080,982  $ 14,696,816
  Three Months


March 31,

Three Months


March 31,

Revenues  $ 5,643,124  $ 6,108,444
Costs and expenses:    
Cost of products sold  3,508,570  3,454,178
Gross profit  2,134,554  2,654,266
Research and development  712,344  463,677
Selling, general and administrative  2,690,843  2,119,760
Operating expenses  3,403,187  2,583,437
Operating (loss) income from continuing operations  (1,268,633)  70,829
Other (income) expense   (2,562)  25,003
(Loss) income from continuing operations before income taxes  (1,266,071)  45,826
Income taxes (benefit)  (20,448)  6,946
(Loss) income from continuing operations  (1,245,623)  38,880
Income from discontinued operations  39,692  168,642
Net (loss) income  $ (1,205,931)  $ 207,522
Loss per share continuing operations --     
Basic and diluted  $ (0.10)  $ 0.00
Income per share discontinued operations --    
Basic and diluted  $ 0.01  $ 0.02
Total (loss) income per share - basic and diluted  $ (0.09)  $ 0.02
Weighted average common shares outstanding --     
Basic   13,011,198  11,343,363
Diluted  13,011,198  12,246,955
CONTACT: CAS Medical Systems, Inc.
         Susan Carron
         Director of Corporate Communications

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com